Skip to main content
Clinical Trials/CTRI/2023/01/048783
CTRI/2023/01/048783
Not yet recruiting
未知

Investigation of efficacy and safety of different iron supplementations in nonanemic to mild anemic adults with iron deficiency and suffering from fatigue. - Nil

Meyer Organics Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Meyer Organics Pvt Ltd
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Meyer Organics Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\.Adult male and females with the age between 18\-65 years old (Both inclusive);
  • 2\.Subjects presenting with fatigue scoring between 18 to 54 based on\-Fatigue Severity Scale (FSS) at screening;
  • 3\.Serum ferritin levels lower than 50 mcg/L (iron deficiency);
  • 4\.Hemoglobin levels \=11 g/dL in non\-pregnant women and men (mild anemic to non\-anemic patients, defined by WHO);
  • 5\.Subjects with or without comorbidity, if comorbid, should be with stable prescription for last three months;
  • 6\.Able to give written informed consent;
  • 7\.Able to follow up through visits.

Exclusion Criteria

  • 1\.Previous diagnosis of any concurrent disease or medical and/or surgical condition as a possible cause of fatigue or iron deficiency;
  • 2\.Medical history of current hematological disorders other than iron deficiency anemia (e.g. aplastic anemia, megaloblastic anemia, sideroblastic anemia, pernicious anemia, thalassemia, sickle cell anemia, etc.).
  • 3\.Medical history of malabsorption syndrome, hypochlorhydria, achlorhydria, gastrectomy, gastrojejunostomy;
  • 4\.Patients who are eligible for IV iron replacement therapy.
  • 5\.Obvious internal or external bleeding as documented by medical history and/or examination if considered clinically significant in the opinion of the investigator
  • 6\.Any treatment with any vitamin and mineral supplements prior to inclusion to the study in the last 3 months’ period;
  • 7\.Participants on dialysis or with an estimated glomerular filtration rate \<30 mL/minute/1\.73 m raise to 2
  • 8\.Ongoing or history of malignancy within past 3 years;
  • 9\.Female participants who are pregnant, intend to become pregnant, are breastfeeding, within 4 weeks postpartum, or have a positive serum/urine pregnancy test;
  • 10\.Known or suspected hypersensitivity to iron or any of the components of investigational products;

Outcomes

Primary Outcomes

Not specified

Similar Trials